Titan Investment Management LLC bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) during the 4th quarter, Holdings Channel reports. The institutional investor bought 2,476 shares of the company’s stock, valued at approximately $1,675,000. IDEXX Laboratories makes up 1.5% of Titan Investment Management LLC’s holdings, making the stock its 26th largest position.
Other institutional investors have also recently bought and sold shares of the company. Virtus Advisers LLC bought a new stake in IDEXX Laboratories in the 3rd quarter valued at $26,000. Park Place Capital Corp acquired a new position in IDEXX Laboratories in the 4th quarter worth $29,000. Mowery & Schoenfeld Wealth Management LLC increased its holdings in IDEXX Laboratories by 58.8% during the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after purchasing an additional 20 shares in the last quarter. Wormser Freres Gestion increased its holdings in IDEXX Laboratories by 671.4% during the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock worth $37,000 after purchasing an additional 47 shares in the last quarter. Finally, WealthCollab LLC acquired a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at about $30,000. Institutional investors own 87.84% of the company’s stock.
Analyst Ratings Changes
A number of brokerages have recently commented on IDXX. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Stifel Nicolaus decreased their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Citigroup initiated coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. Finally, UBS Group cut their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Seven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.
IDEXX Laboratories Price Performance
Shares of NASDAQ IDXX opened at $562.09 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The business’s 50 day moving average price is $562.26 and its two-hundred day moving average price is $621.32. The company has a market cap of $44.34 billion, a PE ratio of 41.39, a price-to-earnings-growth ratio of 2.99 and a beta of 1.55. IDEXX Laboratories, Inc. has a twelve month low of $506.91 and a twelve month high of $769.98.
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period in the prior year, the firm posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.
IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.
Read More
- Five stocks we like better than IDEXX Laboratories
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
